X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cevenfacta (eptacog beta), a new recombinant coagulation Factor VIIa for treatment of bleeding episodes and for prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents with haemophilia A or B with inhibitors.
Lead Product(s): Eptacog Beta
Therapeutic Area: Genetic Disease Product Name: Cevenfacta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
Positive opinions by CHMP were issued as a recommendation for marketing authorization was adopted for Cevenfacta (eptacog beta (activated)). Although FDA has approved SEVENFACT as first bypassing agent in over 20 years for patient with hemophilia A or B with inhibitor in 2020.
Lead Product(s): Eptacog Beta
Therapeutic Area: Genetic Disease Product Name: Cevenfacta
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
Lead Product(s): Eptacog Alfa
Therapeutic Area: Genetic Disease Product Name: Sevenfact
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: HEMA Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
